

17 October 2017

Beta Testing Success for Cloud-Based A.I. Prototype

Resonance Health (ASX: RHT) is pleased to announce that following beta-testing of its ground breaking artificial intelligence (AI) solution, further field testing of the next iteration of the cloud-based solution is planned to commence in November at several large Thalassemia centres in emerging growth markets. Collaboration with the Thalassemia International Federation (TIF) and high-level discussions with key opinion leaders has resulted in a shortlist of key sites of excellence and further rollout is scheduled to commence in parallel with continued testing at the primary site in Vietnam.

User interface and experience upgrades have been designed over the past 30-day trial period, allowing new users to access an improved product offering. Following analysis of results from market research currently underway, it is planned that this next phase will run for a 30-day period. The Stage Two beta testing will continue to focus on evaluating the user-interface and usability of the new cloud-based AI service alongside FerriScan.

Resonance Health's Chief Scientific Officer, Professor Tim St Pierre, attended a meeting of the 1st International Working Group on Thalassemia in September, where MRI and the current management of Thalassemia syndromes, among other things, was discussed. The meeting was an ideal opportunity for the Company to make direct contact with numerous hematologists and radiologists, many from emerging market countries with large numbers of thalassemia patients. The trip proved highly successful in generating global interest from hospital sites for participation in our multi-centre rollout.

Resonance Health would also like to announce that the Company has appointed Alison Laws to the position of Chief Business Development Officer, previously Global Account Manager, to help facilitate the rollout of the new AI solution and to improve overall efficiencies in the commercialization of new products at Resonance Health.

Further updates on the FerriScan AI solution will be provided as work progresses.

Martin Blake

Chairman RHT

For further information please contact:

Alison Laws

Chief Business Development Officer, Resonance Health

E: alisonl@resonancehealth.com P: +61 (0)8 9286 5300